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Human blood monocytes normally express the interleukin-6 receptor. Treatment of cultured monocytes with endotoxin, 
interleukin-l/I, or interleukin-6 results in a decrease of interleukin-6 receptor mRNA levels. Glucocorticoids also cause 
a drop in monocytic interleukin-6 receptor mRNA levels. We also found interleukin-6 receptor expression in cultured 
human hepatocytes, but in contrast to monocytes, where interleukin-6 receptor mRNA is repressed by the ligand and 
by interleukin-I, treatment of hepatocytes with interleukin-6 or interleukin-1 resulted in increased interleukin-6 receptor 
mRNA levels. Induction of interleukin-6 receptor mRNA in hepatocytes was less pronounced when glucocorticoids were 
omitted from the culture medium. We conclude that during noninflammatory homeostasis, blood monocytes are involved 
in binding of trace amounts of circulating interleukin-6. During inflammatory events, the main tissue target of interleukin- 
6 may be changed from the monocytic population not only to activated B-cells, but also to the hepatocytes. 
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1. INTRODUCTION 
Interleukind, previously investigated under the 
designations interferon p2 (IFNm), 26 kDa pro- 
tein, B-cell stimulatory factor 2 (BSF-2), 
hybridoma growth factor (HGF), and hepatocyte- 
stimulating factor (HSF), is synthesized under in- 
flammatory conditions primarily in stimulated 
peripheral blood monocytes [l-4], fibroblasts 
[5-151 and endothelial cells [la-181. The main 
physiological functions of interleukind (IL-6) are: 
the induction of the hepatic acute phase response 
[ 19-271, which is characterized by increased ex- 
pression of acute phase proteins like C-reactive 
protein (CRP); decreased synthesis of albumin and 
the stimulation of preactivated B-cells for im- 
munoglobulin secretion [28-301. 
In order to understand more fully the role of 
IL-6 in the context of inflammatory mediators, it 
is necessary to study the interaction of this 
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molecule with its target cells. Since the 
interleukind receptor (IL-6R) has recently been 
cloned [31], it became possible to examine which 
tissues express this receptor and how its expression 
is regulated. Here, we report expression of the 
interleukind receptor in primary cultures of 
human monocytes and hepatocytes. 
2. MATERIALS AND METHODS 
Endotoxin (Salmonella abortus equl] was a gift of C. 
Galanos, Max-Planck-Institut fur Immunbiologie (Freiburg, 
FRG). Human recombinant interleukin-1,0 was from Biogen 
(Geneva, Switzerland). Human recombinant interleukind was 
either BSF-2 (obtained from T. Kishimoto, University of 
Osaka, Japan) or HGF (obtained from L.A. Aarden, 
Netherlands Red Cross). Interleukin-6 cDNA (pBSF2-38.1) [29] 
and interleukind receptor cDNA (pBSF2R.236) [31] was pro- 
vided by T. Kishimoto. C-reactive protein and albumin cDNA 
was from G. Ciliberto and R. Cortese (EMBL Heidelberg, 
FRG). 
Human blood monocytes were prepared and cultivated as 
described in detail previously by the authors [4]. For the ex- 
periments, cells were kept in RPM1 1640 medium containing 
5% human AB serum. Endotoxin-free conditions during 
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preparation and culture of the cells were strictly observed. All 
media and sera used were tested for trace amounts of endotox- 
ins according to 1321. Primary hepatocyte cultures were 
prepared from fetal liver cells of human fetuses after legal abor- 
tion at 20 weeks of gestation. The cultures were prepared by 
J.B. in G.A.‘s laboratory in New York City according to a pro- 
cedure previously described by this laboratory [33]. 
Hepatocytes used in this study were kept in Ham’s F12 medium 
containing 2% human AB serum, 10e6 dexamethasone, lo-’ in- 
sulin and lo-* glucagon. 
RNA was extracted according to the protocol of Chomczyn- 
ski and Sacchi [34]. Poly(A)+ RNA was prepared by poly(U)- 
Sepharose chromatography. For Northern analysis, as in- 
dicated, either total or poly(A)’ RNA was electrophoresed on 
1.2% agarose-formaldehyde gels and transferred to 
nitrocellulose filters in 20 x SSC. Standardization was done 
with respect to 28 S and 18 S RNA as well as by control 
hybridizations with cDNA coding for the housekeeping protein 
glyceraldehyde-3-phosphate d hydrogenase [35]. Hybridiza- 
tions were performed for 24 h with 32P labeled specific cDNAs 
using 2 x lo6 cpm of labeled probe per ml hybridization buffer 
(6 x SSC, 50% formamide, 0.02 Denhardt’s solution). Filters 
were exposed to Kodak XARS films at -70°C. 
28 S 
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3. RESULTS 
Freshly prepared human blood monocytes ex- 
press the interleukind receptor (ILdR). If 
monocytic RNA was subjected to Northern 
analysis, a strong signal for interleukind receptor 
mRNA (ILdR mRNA) could be detected (fig.lA, 
lane 1; fig.2, lane 1). In addition, we were able to 
show the presence of IL-6R molecules on the 
monocyte surface by fluorescence activated cell 
sorter (FACS) analysis using a monoclonal an- 
tibody directed against the ILdR (not shown; 
Bauer, J. and Kishimoto, T., in preparation). If 
the monocytes were stimulated with endotox- 
in/LPS, a marked and rapid drop in ILdR mRNA 
levels could be observed (fig.lA, lanes 2-4), con- 
comitant with a strong induction of interleukind 
(IL-6) mRNA (fig.lB, lanes l-4). Human recom- 
binant IL-6 could substitute for LPS in reducing 
the interleukind receptor mRNA levels in 
monocytes (fig.2), indicating a repression of the 
monocytic ILdR synthesis by its ligand. Besides 
IL-6, human recombinant IL-la was also able to 
repress IL-6R mRNA in monocytes (not shown). 
Repression of ILdR mRNA by LPS, IL-6 and 
IL-l was time- and dose-dependent. Maximal ef- 
fects were observed with 100 ng LPS/ml, 200 U 
IL-6 (BSF-2 units)/ml, or 100 U -IL-lp, respec- 
tively. 
Fig.1. RNA was extracted from either unstimulated human 
blood monocytes (lane 1) or from cells after different times of 
endotoxin (100 ng/ml) treatment: 4 h (lane 2); 8 h (lane 3); 16 h 
(lane 4). 20/g of total RNA/lane were subjected to agarose- 
formaldehyde lectrophoresis, transferred to nitrocellulose and 
hybridized to radiolabeled interleukind receptor (IL 6R) cDNA 
(A) or interleukind (IL 6) cDNA (B). The filter was exposed to 
the film for 3 days (A) and 15 h (B), respectively. 
not express detectable amounts of ILdR mRNA 
(fig.3A, lanes 1,4). However, the presence of func- 
tioning receptor molecules on the surface of 
unstimulated hepatocytes is indicated by the fact 
that these cells respond to interleukin-6 treatment 
by strong induction of C-reactive protein (CRP) 
1 2 3 4 5 6 
Fig.2. Monocytes were treated with human recombinant 
interleukin-6 (10008 HGF U/ml, equivalent o 50 BSF-2 U/ml) 
for different times: 1 h (lane 2); 3 h (lane 3); 6 h (lane 4); 9 h 
(lane 5); and 18 h (lane 6); control (lane 1). RNA was extracted, 
2O~g of total RNA/lane were electrophoresed through an 
agarose-formaldehyde gel, transferred to nitrocellulose and 
hybridized to radiolabeled interleukind receptor (IL 6R) 
Nonstimulated cultured human hepatocytes do cDNA. Autoradiographic exposure time was 5 days. 
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Fig.3. Primary human fetal hepatocytes were kept in culture for four days. Poly(A)+ RNA was prepared, subjected to agarose- 
formaldehyde lectrophoresis (2.5 pg RNA/lane), blotted onto nitrocellulose, and hybridized to radiolabeled interleukin-6 receptor (IL 
6R) cDNA (A), CRP cDNA (B) or albumin cDNA (C). (A) Before harvesting, cells were treated with human recombinant interleukind 
(100 BSF-2 U/ml) for 12 h (lane 2) or 24 h (lane 3); controls are shown in lanes 1 and 4. Alternatively, cells were treated for 24 h 
with 10 BSF-2 U/ml (lane 5), or 100 BSF-2 U/ml (lane 6); lane 7 represents the experiment of lane 6, except hat glucocorticoids were 
omitted from the culture medium; lane 8, treatment with 100 U interleukin-lj3/ml for 24 h. (B) Lanes l-5 represent he experiments 
of the right part of panel A (panel A, lanes 4-8). (C) Control (lane 1); 24 h of interleukin-6 treatment (100 BSF-2 U/ml) (lane 2). 
mRNA (fig.3B) and by repression of albumin 
mRNA (fig.3C). Upon treatment with IL-6 the 
mRNA levels of IL-6R in hepatocytes increase 
(fig.3A, lanes l-6). If glucocorticoids were omit- 
ted from the culture medium, induction of ILdR 
mRNA by IL-6 was slightly reduced (fig.3A, lane 
7). Besides IL-6, also IL-l,& could induce ILdR 
mRNA in hepatocytes (fig.3A, lane 8). 
4. DISCUSSION 
The interleukin-6 receptor is an 80 kDa 
molecule, which upon binding of the ligand 
associates with a second membrane protein of 
130 kDa, resulting in signal transduction into the 
cell (Kishimoto, T., personal communication). Un- 
til now, expression of interleukind receptor 
mRNA has only been shown in a number of 
leukemic cells [3 11. Since several eukemic cell lines 
express both interleukin-6 and its receptor, it has 
been presumed that this simultaneous expression 
may support an autocrine growth mechanism 
resulting in tumor cell growth [36,37]. The finding 
that monocytes, the main site of IL-6 synthesis, 
also express the IL-6 receptor was therefore rather 
unexpected. However, simultaneous repression of 
the receptor under conditions when interleukin-6 
expression is induced (fig. 1) may indicate the nor- 
mal biological evasion of such an autocrine loop. 
In contrast to interleukind receptor expression 
in monocytes, expression in hepatocytes was ex- 
pected since it has been shown that intravenously 
administered interleukind is cleared primarily by 
the liver [38]. Hepatocytes how an inverse pattern 
of regulation compared to the situation in 
monocytes. Not only is the interleukind receptor 
in these two cell types subjected to contrary regula- 
tion by the ligand, glucocorticoids also had an op- 
posite effect: in hepatocytes, dexamethasone 
augmented ILdR mRNA induction by the ligand 
(fig.3A); in monocytes, treatment with dex- 
amethasone led to a rapid and marked drop in 
IL-6R mRNA levels (not shown). 
In conclusion, our data indicate that under 
conditions of 1 noninflammatory homeostasis 
monocytes strongly express the interleukin-6 recep- 
tor and may be involved in binding trace amounts 
of circulating IL-6. As soon as an inflammatory 
event develops, the tissue target for interleukind 
appears to change from the monocytic population 
to that of the hepatocytes. 
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